Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 3Terminated 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2Thoracic 1Head & Neck 1Gastrointestinal 1Breast 1

Conditions

Pancreatic Neoplasms 23Breast Neoplasms 19Carcinoma, Non-Small-Cell Lung 12Neoplasm Metastasis 11Triple Negative Breast Neoplasms 8Neoplasms 5Small Cell Lung Carcinoma 4Sarcoma 4Ovarian Neoplasms 4Lymphoma, Non-Hodgkin 4Lung Neoplasms 4Hodgkin Disease 4Breast Neoplasms, Male 4Stomach Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Multiple Myeloma 3Urinary Bladder Neoplasms 2Recurrence 2Prostatic Neoplasms 2Melanoma 2Lymphoma 2Head and Neck Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Pancreatic Ductal 2Carcinoma 2Uterine Cervical Neoplasms 1Thrombocytosis 1Stages II-III Breast Cancer 1Spinal Cord Compression 1Rectal Neoplasms 1

Interventions

pembrolizumab 20atezolizumab 9Nivolumab 9Gemcitabine 9Docetaxel 5avelumab 4Mitomycin 4Carboplatin 4fludarabine 3epacadostat 3enfortumab vedotin 3Cyclophosphamide 3vofatamab 2valrubicin 2rucaparib 2pemigatinib 2durvalumab 2cabozantinib 2Standard of Care 2Sirolimus 2Radiation 2Pemetrexed 2Cisplatin 2Bevacizumab 2B701 protein, Human herpesvirus 6 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 2trilaciclib 1temsirolimus 1spartalizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Carcinoma, Transitional Cell × Albumin-Bound Paclitaxel × Clear all
NCT02887248 2023-12-05

Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial Carcinoma

SCRI Development Innovations, LLC

Phase 2 Terminated
3 enrolled 9 charts
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT04060342 2022-08-18

GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma

Gossamer Bio Inc.

Phase 1 Terminated
61 enrolled
BreastGastrointestinalGenitourinaryHead & NeckThoracic

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Stomach Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡